A Phase 3 interventional study of aprepitant and ondansetron in Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-08-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 39th largest by enrollment, is one of 3 that started in 2004, is one of 15 in phase 3, and was the 1st registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2004, is one of 10 in phase 3, and was the 1st registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants treated with emetogenic cancer chemotherapies that include either cisplatin, cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when treated with a previously administered chemotherapy regimen that is planned to be repeated will be enrolled in this study. In the double-blind Part 1 of this study, enrolled participants will be randomized to receive either aprepitant or standard therapy. In Part 2 of this study, enrolled participants will receive open-label aprepitant.
The duration of treatment is the first 4 days of one 28-day cycle (Cycle 1). Participants who successfully complete Cycle 1 may be eligible to participate for 9 subsequent optional, open-label, 28-day cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
Drug: aprepitant · Drug: ondansetron · Drug: dexamethasone · Drug: placebo to dexamethasone · Drug: rescue medication
Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
Drug: ondansetron · Drug: dexamethasone · Drug: placebo to aprepitant · Drug: rescue medication
Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
Drug: aprepitant · Drug: ondansetron · Drug: dexamethasone · Drug: placebo to dexamethasone · Drug: rescue medication
aprepitant capsules
ondansetron IV preparation
dexamethasone tablets
Matching placebo to aprepitant capsules
Matching placebo to dexamethasone tablets
Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1)
Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)
Percentage of Participants Who Experience a Complete Response (CR) to Anti-emetic Therapy (Cycle 1)
Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1
Percentage of Participants Who Experience Absence of Nausea (Cycle 1)
Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1
Percentage of Participants Who Experience Absence of Vomiting (Cycle 1)
Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1
Percentage of Participants Who Experience Serious Adverse Events (Cycles 2-10)
Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)
Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycles 2-10)
Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)
Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycles 2-10)
Time frame: Up to Day 4 of Cycles 2-10 (Up to 10 months)
Percentage of Participants Who Experience Serious Adverse Events (Cycle 1)
Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)
Percentage of Participants Who Experience Serious Study-drug-related Adverse Events (Cycle 1)
Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)
Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycle 1)
Time frame: Up to Day 4 of Cycle 1
Aprepitant Plasma Drug Concentration Profiles and Pharmacokinetics
Time frame: Up to 24 hours after first dose of aprepitant
No study locations are listed for this record.
The record gives a start of Apr 2004, a primary completion of Sep 2006 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant